IntelGenx president and CEO Horst Zerbe said that physicians would embrace CPI-300 as a safe alternative for patients requiring high-dose anti-depressant therapy.
”So we now turn our focus towards the commercialisation of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe added.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Recognised with 2025 Excellence Awards for Research and Development and Marketing, Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.
